Sridevi Kodali, MD
Child & Adolescent Psychiatry · Livonia, MINPI 1053358630
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 356 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 10.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $2,194 and has fallen 85.9% since, to $309 in 2025. Among child & adolescent psychiatry clinicians in MI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 356 payments — averaging $20.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lundbeck LLC$752
- Vanda Pharmaceuticals Inc.$705
- Alkermes, Inc.$684
- Validus Pharmaceuticals LLC$527
- Supernus Pharmaceuticals, Inc.$492
- Sunovion Pharmaceuticals Inc.$442
- plus $4K from 24 others
What the payments were for
- Food & beverage$7,115100%
- Education$70%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lundbeck LLC | 41 | $752 |
| Vanda Pharmaceuticals Inc. | 36 | $705 |
| Alkermes, Inc. | 25 | $684 |
| Validus Pharmaceuticals LLC | 13 | $527 |
| Supernus Pharmaceuticals, Inc. | 28 | $492 |
| Sunovion Pharmaceuticals Inc. | 34 | $442 |
| AbbVie(2 entities) | 22 | $435 |
| Takeda Pharmaceuticals U.S.A., Inc. | 25 | $398 |
| Otsuka America Pharmaceutical, Inc. | 21 | $373 |
| Ironshore Pharmaceuticals Inc. | 20 | $366 |
| Teva Pharmaceuticals USA, Inc. | 15 | $360 |
| Axsome Therapeutics, Inc. | 5 | $331 |
| Corium, LLC | 14 | $229 |
| Almatica Pharma LLC | 8 | $193 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 9 | $177 |
| Tris Pharma Inc | 8 | $120 |
| Neurocrine Biosciences, Inc. | 3 | $61 |
| Neos Therapeutics, LP | 4 | $60 |
| Bausch Health US, LLC | 4 | $57 |
| Johnson & Johnson(2 entities) | 3 | $54 |
| Idorsia Pharmaceuticals US Inc | 2 | $45 |
| Eisai Inc. | 2 | $42 |
| Shire North American Group Inc | 3 | $42 |
| E.r. Squibb & Sons, L.L.C. | 2 | $38 |
| Indivior Inc. | 2 | $37 |
| Vertical Pharmaceuticals, LLC | 2 | $30 |
| Adlon Therapeutics L.p. | 2 | $24 |
| Livanova USA, Inc. | 1 | $20 |
| Merck | 1 | $18 |
| Acadia Pharmaceuticals Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$401
- Equetro$276
- Auvelity$250
- UZEDY$115
- ARISTADA INITIO$100
How this compares
$7,122 in reported general payments places this provider in the 90th percentile of 73 child & adolescent psychiatry providers in Michigan.
See all child & adolescent psychiatry providers in Michigan →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Aripiprazole | 101 | $9,371 |
| Lurasidone Hcl | 36 | $8,108 |
| Bupropion Hcl SrBupropion Hcl | 110 | $2,143 |
| Bupropion XlBupropion Hcl | 106 | $1,849 |
| Methylphenidate Er (La)Methylphenidate Hcl | 11 | $1,794 |
| Methylphenidate ErMethylphenidate Hcl | 11 | $1,680 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 22 | $1,512 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 47 | $1,445 |
| Escitalopram Oxalate | 129 | $1,363 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 52 | $1,346 |
| Sertraline Hcl | 141 | $1,325 |
| Duloxetine Hcl | 63 | $1,182 |
| Atomoxetine Hcl | 15 | $1,088 |
| Trazodone Hcl | 93 | $988 |
| Alprazolam | 198 | $707 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Almatica Pharma LLCSertraline Hcl | $193 | $1,325141 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 73 child & adolescent psychiatry providers in Michigan.
Other child & adolescent psychiatry in Livonia
- Carol Crouch-RossLivonia$24K
- Birgit AmannTroy$980K
- David VillanuevaSterling Heights$140K
- Robert GarciaNorthville$24K
- Gerald SchmukerSpring Lake$11K
- Mohammad JafferanySaginaw$10K
- Viken MatossianHowell$5K
- Seema KumarWest Bloomfield$4K
- Davinder KakarBloomfield Hills$3K
- Meenakumari NannapaneniSouthfield$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.